Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14212559 | 1.00 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL16472314 | 0.74 | CHRNB2 (0.46) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL24652814 | 0.73 | NR1H2 (0.46) | PDK2RORCSMN1; SMN2 | |
| SCHEMBL21216450 | 0.73 | NR1H2 (0.46) | PDK2RORCSMN1; SMN2 | |
| SCHEMBL23580354 | 0.73 | NR1H2 (0.46) | PDK2RORCSMN1; SMN2 | |
| SCHEMBL28850046 | 0.71 | NR1H2 (0.33) | RORC | |
| SCHEMBL14752967 | 0.69 | — | — | |
| SCHEMBL15014466 | 0.68 | — | — | |
| Hydrochloric Acid SCHEMBL28957871 | 0.68 | CHRNB2 (0.55) | CHRNB2CHRNA4CHRNB4CHRNA3TSHR | |
| SCHEMBL21196146 | 0.67 | VNN1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-9931353-B2 | Method for treating cerebral amyloid angiopathy using pharmacological chaperones to increase the activity of gangliosidases | AMICUS THERAPEUTICS, INC. (US) | 2018-04-03 | — | — | US | disclosed |
| US-9409862-B2 | Compositions for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-20150374733-A1 | Method for Treating Cerebral Amyloid Angiopathy Using Pharmacological Chaperones to Increase the Activity of Gangliosidases | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2015-12-31 | — | — | US | disclosed |
| US-20140086896-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | AMICUS THERAPEUTICS, INC. (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140080871-A1 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System | AMICUS THERAPEUTICS, INC. (US) | 2014-03-20 | — | — | US | disclosed |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080871-A1 | Novel Compositions for Preventing and/or Treating Degenerative Disorders of the Central Nervous System | GAP43, CHAT, PMP22 | CHRNB2 19/4885CHRNA4 25/4885CHRNB4 18/4885 |
| US-20110091442-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, MAN2B1 | CHRNB2 2642/4885CHRNA4 3395/4885CHRNB4 2891/4885 |
| US-20110092541-A1 | NOVEL COMPOSITIONS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | GAP43, CHAT, PMP22 | CHRNB2 19/4885CHRNA4 25/4885CHRNB4 18/4885 |
| US-10035766-B2 | Compositions for preventing and/or treating lysosomal storage disorders | GAA, GBA1, MAN2B1 | CHRNB2 2843/4885CHRNA4 3398/4885CHRNB4 3100/4885 |
| US-20140086896-A1 | Novel Compositions for Preventing and/or Treating Lysosomal Storage Disorders | GAA, GBA1, MAN2B1 | CHRNB2 2642/4885CHRNA4 3395/4885CHRNB4 2891/4885 |
| US-20150374733-A1 | Method for Treating Cerebral Amyloid Angiopathy Using Pharmacological Chaperones to Increase the Activity of Gangliosidases | GBA1, ASAH2, ASAH1 | CHRNB2 880/4885CHRNA4 1322/4885CHRNB4 1155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.